Did lurbinectedin's adverse effects cause treatment delays?

Yes. In clinical use and in trials, adverse effects from lurbinectedin can lead to treatment delays or dose adjustments. The main issues are:

- Hematologic toxicity: neutropenia, thrombocytopenia, and anemia are common enough to cause delays or require dose reductions in subsequent cycles.
- Hepatic toxicity: elevations in liver enzymes (AST/ALT) and other liver function abnormalities can also lead to holding a cycle or reducing the dose.

How this is managed (per typical labeling/guidelines):
- Cycles are often delayed until blood counts recover to certain thresholds (e.g., ANC and platelets recover to predefined levels).
- Dose reductions or omissions are allowed for subsequent cycles if a patient experiences grade 3–4 toxicities.
- For hepatic impairment or persistent liver enzyme elevations, dose modifications or discontinuation may be recommended.

If you want, I can quote the exact thresholds and modification rules from the current labeling or summarize the trial data that reported delays due to adverse events. Tell me which you’d prefer.